Richard D. Francis - 15 Feb 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
President and CEO
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis
Issuer symbol
TEVA
Transactions as of
15 Feb 2026
Net transactions value
-$15,324,799
Form type
4
Filing time
18 Feb 2026, 16:01:11 UTC
Previous filing
29 Jan 2026
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Francis Richard D President and CEO C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis 18 Feb 2026 0001673277

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +161,656 +59% 433,439 15 Feb 2026 Direct F1, F2
transaction TEVA Ordinary Shares Sale $5,532,531 -161,656 -37% $34.22 271,783 15 Feb 2026 Direct F1, F3, F4, F5
transaction TEVA Ordinary Shares Options Exercise +620,110 +228% 891,893 15 Feb 2026 Direct F1, F2
transaction TEVA Ordinary Shares Sale $9,792,268 -286,122 -32% $34.22 605,771 15 Feb 2026 Direct F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -161,656 -100% $0.000000 0 15 Feb 2026 Ordinary Shares 161,656 Direct F1, F2, F6
transaction TEVA Restricted Share Units Options Exercise $0 -620,110 -100% $0.000000 0 15 Feb 2026 Ordinary Shares 620,110 Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.
F4 Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.015 to $34.51, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 Restricted share units were granted on February 15, 2023, with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vested on February 15, 2026.
F7 Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on February 15, 2026, following satisfaction of the time-based vesting criteria.